79 related articles for article (PubMed ID: 16340850)
1. [Improved prognosis in non small cell lung cancer--myth or reality?].
Milleron B; Lavolé A; Gounant V
Rev Mal Respir; 2005 Dec; 22(6 Pt 2):8S137-42. PubMed ID: 16340850
[TBL] [Abstract][Full Text] [Related]
2. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
3. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments.
van Meerbeeck JP; Surmont VF
Lung Cancer; 2009 Sep; 65(3):257-67. PubMed ID: 19285751
[TBL] [Abstract][Full Text] [Related]
4. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
Huang EH; Liao Z; Cox JD; Guerrero TM; Chang JY; Jeter M; Borghero Y; Wei X; Fossella F; Herbst RS; Blumenschein GR; Moran C; Allen PK; Komaki R
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):779-85. PubMed ID: 17418967
[TBL] [Abstract][Full Text] [Related]
5. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
[TBL] [Abstract][Full Text] [Related]
6. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
7. [Early stages of non small cell lung cancer (I. II. IIIA). Role of preoperative treatments].
Depierre A
Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S43-16S46. PubMed ID: 17268335
[TBL] [Abstract][Full Text] [Related]
8. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
[TBL] [Abstract][Full Text] [Related]
9. [Lung cancer].
Tsuboi M; Kato H
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1538-42. PubMed ID: 17940368
[TBL] [Abstract][Full Text] [Related]
10. [The effect of haemoglobin levels on prognosis and quality of life of patients with bronchial carcinoma].
Drings P; Wannenmacher M
Dtsch Med Wochenschr; 2005 Jun; 130(24):1507-11. PubMed ID: 15942841
[TBL] [Abstract][Full Text] [Related]
11. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.
Dediu M; Crisan E; Radut M; Tarlea A; Median D; Alexandru A; Vremes G; Gal C
Lung Cancer; 2009 Feb; 63(2):271-6. PubMed ID: 18565617
[TBL] [Abstract][Full Text] [Related]
12. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
13. The "Will Rogers effect" on stage grading.
Testa T; Nahum MA; Spinelli E; Carbone E; Flocchini GP; Motta G
Ann Ital Chir; 1999; 70(6):829-30. PubMed ID: 10804656
[TBL] [Abstract][Full Text] [Related]
14. Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival.
Steger V; Walles T; Kosan B; Walker T; Kyriss T; Veit S; Dippon J; Friedel G
Ann Thorac Surg; 2009 Jun; 87(6):1676-83. PubMed ID: 19463576
[TBL] [Abstract][Full Text] [Related]
15. Early-stage NSCLC: the role of radiotherapy and systemic therapy.
Bunn PA
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S31-40. PubMed ID: 19780244
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with true pathologic stage I non-small cell lung cancer.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2009 Sep; 88(3):917-22; discussion 922-3. PubMed ID: 19699920
[TBL] [Abstract][Full Text] [Related]
17. [A comparison of efficacy of different modalities of treatment for locally-advanced and metastatic non-small lung cancer].
Arsen'ev AI; Barchuk AS; Kanaev SV; Shulepov AV; Morozova IuA; Barchuk AA; Tarkov SA; Vedenin IaO
Vopr Onkol; 2008; 54(3):281-6. PubMed ID: 18652231
[TBL] [Abstract][Full Text] [Related]
18. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
[TBL] [Abstract][Full Text] [Related]
19. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.
Higgins K; Chino JP; Marks LB; Ready N; D'Amico TA; Clough RW; Kelsey CR
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1462-7. PubMed ID: 19467798
[TBL] [Abstract][Full Text] [Related]
20. Combined modality therapy for stage III non-small cell lung cancer.
Stinchcombe TE; Fried D; Morris DE; Socinski MA
Oncologist; 2006; 11(7):809-23. PubMed ID: 16880240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
